#United States #Raleigh #FDA Clearance #Zeto New Wave #EEG System

Zeto's New Wave EEG System: A Game Changer for Outpatient Care

Zeto, Inc., a pioneering company in medical technology, has recently announced the FDA's 510(k) clearance for its innovative EEG system, the Zeto New Wave™. This new system aims to significantly enhance the efficiency and accessibility of electroencephalogram (EEG) testing in outpatient settings, ensuring patients receive timely neurological care.

Addressing Delays in EEG Testing

In the current healthcare landscape, patients in the United States frequently experience long wait times—often stretching to weeks—for EEG appointments. This delay can hinder critical diagnosis and treatment, particularly for those suffering from neurological conditions. Overburdened clinics are faced with staffing shortages of specialized EEG technologists and have been relying on outdated, cumbersome setups. These factors contribute to delays not just in testing, but also in the necessary follow-up care that patients urgently need.

Recognizing these challenges, Zeto designed the New Wave™ system as a streamlined solution. It features full head coverage utilizing 21 soft-tip electrodes, applied using the established 10-20 electrode placement system. This setup aims to eliminate the mess often associated with traditional EEG applications while maintaining high standards for data accuracy.

Cutting-Edge Features for Improved Patient Care

The Zeto New Wave™ system is not just user-friendly; it represents a technological leap forward in outpatient EEG testing. The system comes equipped with a compact recording device, which includes a built-in display for immediate feedback and controls to facilitate operation.

Additionally, it offers synchronized video and audio capture, along with optional data for signals such as ECG, EOG, EMG, and orientation sensors. The unit is designed to handle short-term recordings of up to 2.5 hours, making it ideal for quick evaluations, a feature that will help clinics operate more efficiently and serve more patients.

Florian Strelzyk, PhD, the CEO of Zeto, highlighted the system's development. He stated, "New Wave™ is our newest outpatient EEG system, built on lessons learned from our first-generation device, the Zeto WR19. We listened to neurologists' needs and designed a system that helps clinics expand access to EEG, address staffing challenges, and improve patient experience." This is indicative of Zeto's commitment to innovation driven by direct feedback from healthcare professionals.

In 2024, Zeto introduced the ONE™ EEG system specifically tailored for ICUs and emergency departments. With the addition of the New Wave™, Zeto now offers flexible options tailored for various healthcare settings, allowing providers to choose the system that best fits their operational needs and budget.

A Commitment to Brain Health

The clearance of Zeto New Wave™ marks a significant milestone as Zeto's third FDA-cleared device, joining the ranks of the Zeto WR19 and ONE systems. Zeto continues to offer a variety of EEG solutions that support critical and emergency care, academic research, and outpatient clinics. Notably, the company also incorporates AI technology for seizure detection and analysis, which enhances the functionality of their EEG systems.

Zeto, Inc. is dedicated to revolutionizing brain health assessments, aiming to make EEG measurements as commonplace as other vital signs. Their mission includes improving access to EEG testing and facilitating ground-breaking biomedical research.

As these technologies mature, Zeto envisions a future where reliable neurodiagnostic insights enhance everyday clinical decision-making processes, thereby improving overall patient outcomes. Their systems, which have already received FDA clearances in 2018, 2024, and now 2026, are commercially available throughout the United States.

To find out more about Zeto's innovative EEG solutions, visit zeto-inc.com.